OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, September 09, 2016

Ontario won’t set up body to examine sex-abuse complaints against doctors (update/report)



The Globe and Mail
  

Ontario won’t set up body to examine sex-abuse complaints against doctors


The Ontario government will not set up an independent body to investigate sexual-abuse complaints against doctors, rejecting one of the top recommendations from its own task force on protecting patients from sexual violations.
The Ministry of Health and Long-Term Care finally released the recommendations of the panel, which began its work nearly two years ago, on Friday.....

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy....



abstract:
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
 This trial is ongoing and is registered with ClinicalTrials.gov, number NCT00753545.

Summary

Background

In patients with platinum-sensitive recurrent serous ovarian cancer, maintenance monotherapy with the PARP inhibitor olaparib significantly improves progression-free survival versus placebo. We assessed the effect of maintenance olaparib on overall survival in patients with platinum-sensitive recurrent serous ovarian cancer, including those with BRCA1 and BRCA2 mutations (BRCAm).

Methods

In this randomised, placebo-controlled, double-blind, phase 2 trial involving 82 sites across 16 countries, patients with platinum-sensitive recurrent serous ovarian cancer who had received two or more courses of platinum-based chemotherapy and had responded to their latest regimen were randomly assigned (1:1) using a computer-generated sequence to receive oral maintenance olaparib (as capsules; 400 mg twice a day) or a matching placebo by an interactive voice response system. Patients were stratified by ancestry, time to progression on penultimate platinum, and response to most recent platinum. Patients and investigators were masked to treatment assignment by the use of unique identifiers generated during randomisation. The primary endpoint of the trial was progression-free survival. In this updated analysis, we present data for overall survival, a secondary endpoint, from the third data analysis after more than 5 years' follow-up (intention-to-treat population). We did the updated overall survival analysis, described in this Article at 77% data maturity, using a two-sided α of 0·95%. As the study was not powered to assess overall survival, this analysis should be regarded as descriptive and the p values are nominal.

Gynecological cancers: A summary of published Indian data



open access

http://journal.sajc.org/images/logo.gif

Abstract

Gynecological cancers are among the most common cancers in women and hence an important public health issue. Due to the lack of cancer awareness, variable pathology, and dearth of proper screening facilities in developing countries such as India, most women report at advanced stages, adversely affecting the prognosis and clinical outcomes. Ovarian cancer has emerged as one of the most common malignancies affecting women in India and has shown an increase in the incidence rates over the years. Although cervical cancer is on a declining trend, it remains the second most common cancer in women after breast cancer. Many researchers in India have published important data in the field of gynecologic oncology, covering all domains such as basic sciences, preventive oncology, pathology, radiological imaging, and clinical outcomes. This work has given us an insight into the in-depth understanding of these cancers as well as the demographics and survival rates in the Indian population. This aim of this review is to discuss the important studies done in India for all gynecological cancers.

MLH1 Ile219Val Polymorphism in Argentinean Families with Suspected Lynch Syndrome (no ovarian cancers found)



open access

Patient Selection

The Hereditary cancer registry of the Hospital Italiano de Buenos Aires is a national Argentinean registry that contains information of all families identified with proven or suspected hereditary cancer. Through research collaborations, data from the registry is freely available. This prospective database contains clinical, molecular, and familial data, which is clinically relevant. In addition, the electronic medical records of these patients can be reviewed to retrieve further data.
We obtained molecular (genetic testing) and epidemiological data (family history) from 48 families that fulfilled AC (n = 33), Bethesda guidelines criteria (n = 8), and families suggestive of a dominant CRC inheritance syndrome (n = 7) (7, 8, 24) between 2009 and 2016. Family pedigree was constructed based on the information provided by the proband during one or more genetic counseling sessions.

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies



open access

Thursday, September 08, 2016

report due publicly Sept 9th: Task force calls for independent body to probe alleged sex abuse by doctors



media

 A provincial task force has called for an independent body to take over the task of investigating sexual assault allegations against health-care professionals

Health Canada recalls Sage Product cleansing cloths



recalls Sage Product cleansing cloth

 http://i.cbc.ca/1.3753944.1473368778!/fileImage/httpImage/image.jpg_gen/derivatives/16x9_620/sage-product-recall.jpg

Therapeutic and Preventive Implications of Moonshot in Hereditary Cancer Syndromes



JAMA Oncology 
 

Full content is available to subscribers

Subscribe/Learn More
Viewpoint |

Osama Diab, MD1; Lakshmi Manogna Chintalacheruvu, MBBS1; Henry T. Lynch, MD2
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3046

This Viewpoint discusses the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing.
An announcement was made regarding the initiation of a “moonshot” approach to the multifaceted cancer problems with the intent on reducing cancer mortality in the United States by accelerating cancer research to discover more therapies and focusing on finding new ways to prevent cancer and detect it in an early stage before it spreads. President Obama’s proposed fiscal year 2017 budget includes $1 billion for eliminating cancer. This initiative has led to the belief that concentrating on treatment is a limited approach to the overall reduction of cancer mortality, considering the success of cancer research in prevention.1 However, a powerful method for cancer prevention and survival has been the discipline of hereditary cancer syndromes. In this article, we discuss the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing (NGS).

Therapeutic and Preventive Implications of Moonshot in Hereditary Cancer Syndromes



JAMA Oncology 
 

Full content is available to subscribers

Subscribe/Learn More
Viewpoint |

Osama Diab, MD1; Lakshmi Manogna Chintalacheruvu, MBBS1; Henry T. Lynch, MD2
JAMA Oncol. Published online September 08, 2016. doi:10.1001/jamaoncol.2016.3046

This Viewpoint discusses the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing.
An announcement was made regarding the initiation of a “moonshot” approach to the multifaceted cancer problems with the intent on reducing cancer mortality in the United States by accelerating cancer research to discover more therapies and focusing on finding new ways to prevent cancer and detect it in an early stage before it spreads. President Obama’s proposed fiscal year 2017 budget includes $1 billion for eliminating cancer. This initiative has led to the belief that concentrating on treatment is a limited approach to the overall reduction of cancer mortality, considering the success of cancer research in prevention.1 However, a powerful method for cancer prevention and survival has been the discipline of hereditary cancer syndromes. In this article, we discuss the significance of investing billions of dollars in genomic sequencing and the implications of finding a hereditary mutation in patients with metastatic cancer using next-generation sequencing (NGS).

Doctors and Discontent: The Doctors vs. The Province (Ontario) video (43:27 min)



TVO.org
  Doctors and Discontent
Air Date: 
Sep 06, 2016
Length: 
43:27
About this Video
After long and unsuccessful negotiations, it looked like the province and the Ontario Medical Association had finally hammered out a new contract for doctors - until it was rejected by an overwhelming two to one margin. The Agenda looks at one of the biggest stories of the summer and what lies ahead for Ontario's health care system and for patient care.

Lessons Learned for Online Health Community Moderator Roles: A Mixed-Methods Study of Moderators Resigning From WebMD Communities



open access:
Lessons Learned for Online Health Community Moderator Roles: A Mixed-Methods Study of Moderators Resigning From WebMD Communities | Huh | Journal of Medical Internet Research


Background: Online health community (OHC) moderators help facilitate conversations and provide information to members. However, the necessity of the moderator in helping members achieve goals by providing the support they need remains unclear, with some prior research suggesting that moderation is unnecessary or even harmful for close-knit OHCs. Similarly, members’ perceptions of moderator roles are underexplored. Starting January of 2013, WebMD moderators stopped working for WebMD communities. This event provided an opportunity for us to study the perceived role of moderators in OHCs.
Objective: We examine the OHC members’ perception on OHC moderators by studying their reactions toward the departure of moderators in their communities. We also analyzed the relative posting activity on OHCs before and after the departure of moderators from the communities among all members and those who discussed moderators’ departures.
Methods: We applied a mixed-methods approach to study the posts of all 55 moderated WebMD communities by querying the terms relating to discussions surrounding moderators’ disappearance from the WebMD community. We performed open and axial coding and affinity diagramming to thematically analyze patients’ reactions to the disappeared moderators. The number of posts and poster groups (members and moderators) were analyzed over time to understand posting patterns around moderators’ departure.
Results: Of 821 posts retrieved under 95 threads, a total of 166 open codes were generated. The codes were then grouped into 2 main themes with 6 total subthemes. First, patients attempted to understand why moderators had left and what could be done to fill the void left by the missing moderators. During these discussions, the posts revealed that patients believed that moderators played critical roles in the communities by making the communities vibrant and healthy, finding solutions, and giving medical information. Some patients felt personally attached with moderators, expressing they would cease their community participation. On the other hand, patients also indicated that moderators were not useful or sometimes even harmful for peer interactions. The overall communities’ posting activity, which was already in decline, showed no significant difference before and after the moderators’ departure. In fact, the overall posting activities of the communities were declining well before the moderators’ departure. These declining posting activities might be the reason why WebMD removed the moderators.
Conclusion: Compassionate moderators who provide medical expertise, control destructive member posts, and help answer questions can provide important support for patient engagement in OHCs. Moderators are in general received positively by community members and do not appear to interfere with peer interactions. Members are well aware of the possibility of misinformation spreading in OHCs. Further investigation into the attitudes of less vocal community members should be conducted.

J Med Internet Res 2016;18(9):e247

Introduction

In-person patient support groups, often organized by hospitals and clinical moderators, are a well-established mechanism to encourage peer-patient interaction, help patients improve self-efficacy, and educate patients about self-care management [1-4]. As Web 2.0 and social media spread as one of the main Internet activities, OHCs have also proliferated, often without moderators [5]. Unmoderated communities can suffer from the negative consequences of misinformation and poor social dynamics (eg, trolling) if not well-maintained by community members [6-8], especially when the interest of the community is health. The addition of moderators or active commitment by the members can diminish such negative consequences of OHCs [6-9]. However, the cost of resources is high for hiring moderators, preferably those with clinical backgrounds. In addition, moderating thousands of posts [5], and motivating moderators to voluntarily participate in OHCs can be difficult [10].
To successfully administer OHCs, we need to understand the critical role that moderators have in OHCs. A study revealed effective moderation styles for various negative online behaviors (eg, trolling) [11]. Although the effectiveness of moderation styles (eg, rewarding vs punishing) has been studied, there is no consensus regarding the necessity and role of moderators on OHC retention and improving levels of social support, where prior research reveals conflicting results. A study showed that moderators may be important for both the vibrancy of forums and improving patient outcomes [7,12]. Moderators review postings, redirect conversations, and stimulate dialogue when forum activity lags. They also execute a “process function” and help establish and enforce community rules [13]. Moderators offer valuable help that clinicians cannot provide, including suggesting ways to communicate with health care providers and finding useful health information resources for self-management [14]. The necessity of such external governance in moderating troll conversations may be dependent on the specific community. For those OHCs where patients have already established strong rapport with one another and are self-policing community conversations, external governance can be unnecessary [15] or sometimes even disruptive [16]. Online health communities independently run by patients only can self-maintain high information quality [17], although a systematic review showed that the effectiveness of purely peer-patient–based OHCs in terms of clinical outcomes lacks RCT-based evidence [18]......

Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer



Medscape

 Chemotherapy Toxicity
More than one half of patients in the validation cohort (58%) experienced grade 3 to 5 toxicity compared with 53% of patients in the development cohort (). Of patients in the validation cohort, 34% experienced hematologic toxicity and 55% experienced nonhematologic toxicity. The most frequent hematologic toxicities were grade 3 absolute neutrophil count (12%) and grade 3 anemia (7%). The most frequent nonhematologic toxicities were grade 3 fatigue (20%) and grade 3 infections (10%). Of patients in both the development and validation cohorts, 2% died as a result of chemotherapy toxicity.

 This study has some important limitations. Although the model was able to discriminate toxicity risk better than KPS, it was less able to discriminate between moderate and high-risk toxicity than we expected on the basis of the development study. Therefore, the tool may be best used in distinguishing patients at a lower than average risk versus those who are at a higher than average risk for chemotherapy toxicity
Purpose Older adults are at increased risk for chemotherapy toxicity, and standard oncology assessment measures cannot identify those at risk. A predictive model for chemotherapy toxicity was developed (N = 500) that consisted of geriatric assessment questions and other clinical variables. This study aims to externally validate this model in an independent cohort (N = 250).
Patients and Methods Patients age ≥ 65 years with a solid tumor, fluent in English, and who were scheduled to receive a new chemotherapy regimen were recruited from eight institutions. Risk of chemotherapy toxicity was calculated (low, medium, or high risk) on the basis of the prediction model before the start of chemotherapy. Chemotherapy-related toxicity was captured (grade 3 [hospitalization indicated], grade 4 [life threatening], and grade 5 [treatment-related death]). Validation of the prediction model was performed by calculating the area under the receiver-operating characteristic curve.

Everyone Knows Someone (impacted by ovarian cancer): Joe Girardi (New York Yankees)- YouTube



Everyone Knows Someone: Joe Girardi - YouTube (1:26 min)

  Joe Girardi, manager of the New York Yankees, lost his mother Angela to ovarian cancer while he was a student-athlete at Northwestern University. “My mother, Angela, was a small Italian woman who was kind but tough on us about our education,” said Girardi. “I feel fortunate that my mother was given three to six months to live, and she lived six years. But golly, I sure would have liked to have sixteen or twenty-six years with her.” Watch his story here.

top 10 recommendations: Blue Ribbon Panel Report - BRP - Cancer Moonshot (videos)e



Blue Ribbon Panel Report

 The Blue Ribbon Panel presented its report to the National Cancer Advisory Board on September 7, 2016. The report describes 10 transformative research recommendations for achieving the Cancer Moonshot's ambitious goal of making a decade's worth of progress in cancer prevention, diagnosis, and treatment in just 5 years.

eg.

 

Cancer Moonshot Recommendations Highlight Precision Medicine, Data Sharing, Genetic Screening



GenomeWeb